Notably, similar patterns of dysregulation are observed in inflammation-associated cancers, such as pancreatic ductal adenocarcinoma, gastrointestinal malignancies, and primary liver cancer, raising the possibility that REG3A could serve as a diagnostic or prognostic biomarker. The gene discussed is REG3A; the disease is liver cancer.